	•	OIPE	wij.			Choo	. 1 of 1
		- Low 0 5 201	n il				ot <u>1</u> of <u>1</u>
FORM PTO-1449 U.S. Dept. of Commerce Atty Docket No.						Serial No.	
Patent and Trademark Office					P1096R1	1 09/102,865	
LIS	r of D	ISCLOSURES CITED E	BY APPLICANT	ration and maconian oniso	Applicant Raju		
(Use several sheets if necessary)					Filing Date 23 Jun 1998		
				U.S. PATENT DOCUMENTS			
Examine Initials	r	Document Number	Date	Name	Class	Subclass	Filing Date
1881	89	5,180,674	11993	Roth		_	-
(17)	90	5,728,554	3)1988	Bayer et al.			
				FOREIGN PATENT DOCUMENTS	<b>S</b>		
Examine Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
JhB1	91	WO 99/54342	10/1999	DCF. U ()			
				OSURES (Including Author, Title, Date,	• .	•	
MS	92	Exp. Rheumatol. 1		capacity of asialyl and agalact	osyl IgG to Fc ga	mma recept	ors" Clin.
117	93	Furukawa et al., "Kinetic study of a galactosyltransferase in the B cells of patients with rheumatoid					
	94						
	95	Newkirk, M.W. et al., "Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice" Clin. Exp. Immunol. 106:259-264 (1996)					
	96	Parekh et al., "Age-related galactosylation of the N-linked oligosaccharides of human serum IgG" <u>Journal of Experimental Medicine</u> 167:1731-1736 (1988)					
	97	glycosylation pat	tern of total s	on of rheumatoid arthritis and p serum IgG" <u>Nature</u> 316:452-457 (1	985)		
1	98	Youings, Adrian et al, "Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients" <u>Biochemical Journal</u> 314:621-630 (1996)					
					•		
						_	
							) 900
			^				<b>VEL</b> 2002 600/7
Examine	er	Van 1		Da	ite Considered	1 [	) E I 0 7 TEB :
*Examir if not	er: In in con	itial if reference consider formance and not consi	ered, whether or no dered. Include cop	t citation is in conformance with MPEP of this form with next communication t	609; draw line through	citation	NOV 0 7 2002 CH CENTER 1600/2900